| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $90,209 | 5 | 71 |
Sells | $82,294 | 2 | 29 |
| Sebelius Kathleen | director | 1 | $50,000 | 0 | $0 | $50,000 |
| Jones Keith Anthony | director | 3 | $30,370 | 0 | $0 | $30,370 |
| Constantino Michael T. | director | 1 | $9,840 | 0 | $0 | $9,840 |
| Parikh Shamik J | Chief Medical Officer | 0 | $0 | 1 | $41,147 | $-41,147 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | 0 | $0 | 1 | $41,147 | $-41,147 |
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing …
Over the last 12 months, insiders at Humacyte, Inc. have bought $90,209 and sold $82,294 worth of Humacyte, Inc. stock.
On average, over the past 5 years, insiders at Humacyte, Inc. have bought $370,709 and sold $41.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sebelius Kathleen (director) — $50,000. Jones Keith Anthony (director) — $30,370. Constantino Michael T. (director) — $9,840.
The last purchase of 10,000 shares for transaction amount of $5,620 was made by Jones Keith Anthony (director) on 2026‑09‑14.
| 2026-09-14 | Jones Keith Anthony | director | 10,000 0.0043% | $0.56 | $5,620 | -16.23% | ||
| 2026-08-20 | Jones Keith Anthony | director | 10,000 0.0061% | $0.69 | $6,930 | -20.76% | ||
| 2026-08-17 | Jones Keith Anthony | director | 30,000 0.0136% | $0.59 | $17,820 | -1.61% | ||
| 2026-05-19 | Sebelius Kathleen | director | 56,818 0.0361% | $0.88 | $50,000 | -21.03% | ||
| 2026-05-18 | Sale | Parikh Shamik J | Chief Medical Officer | 45,887 0.0273% | $0.90 | $41,147 | -27.27% | |
| 2026-05-18 | Sale | Sander Dale A. | CFO and Chief Corp. Dev. Off | 45,887 0.0273% | $0.90 | $41,147 | -27.27% | |
| 2026-05-18 | Constantino Michael T. | director | 11,000 0.0065% | $0.89 | $9,840 | -27.27% | ||
| 2025-08-20 | Sale | Niklason Laura E | President, CEO and Director | 591,685 0.3621% | $1.58 | $934,862 | -32.52% | |
| 2025-08-20 | Sale | Dougan Brady W | director | 591,685 0.3621% | $1.58 | $934,862 | -32.52% | |
| 2025-08-19 | Sale | Niklason Laura E | President, CEO and Director | 1.1M 0.7098% | $1.63 | $1.79M | -30.63% | |
| 2025-08-19 | Sale | Dougan Brady W | director | 1.1M 0.7098% | $1.63 | $1.79M | -30.63% | |
| 2025-08-18 | Sale | Niklason Laura E | President, CEO and Director | 549,360 0.3527% | $1.83 | $1.01M | -38.33% | |
| 2025-08-18 | Sale | Dougan Brady W | director | 549,360 0.3527% | $1.83 | $1.01M | -38.33% | |
| 2025-04-14 | Scheessele William John | Chief Commercial Officer | 6,493 0.0051% | $1.54 | $9,999 | -2.01% | ||
| 2025-04-10 | Sander Dale A. | CFO and Chief Corp. Deve. Off. | 20,000 0.0157% | $1.53 | $30,600 | -7.01% | ||
| 2025-04-10 | Parikh Shamik J | Chief Medical Officer | 7,500 0.0059% | $1.55 | $11,625 | -7.01% | ||
| 2025-04-08 | Sebelius Kathleen | director | 50,000 0.0338% | $1.32 | $66,000 | +27.83% | ||
| 2025-04-08 | Green Charles Bruce | director | 6,000 0.004% | $1.29 | $7,740 | +27.83% | ||
| 2025-04-07 | Constantino Michael T. | director | 16,000 0.0103% | $1.26 | $20,160 | +16.67% | ||
| 2024-12-04 | Constantino Michael T. | director | 4,600 0.0036% | $4.39 | $20,181 | -49.66% |
| Parikh Shamik J | Chief Medical Officer | 272713 0.0982% | $120,130.08 | 1 | 1 | <0.0001% |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | 267213 0.0962% | $117,707.33 | 3 | 2 | <0.0001% |
| Sebelius Kathleen | director | 148025 0.0533% | $65,205.01 | 2 | 1 | +27.83% |
| Jones Keith Anthony | director | 50000 0.018% | $22,025.00 | 3 | 0 | |
| Constantino Michael T. | director | 43950 0.0158% | $19,359.98 | 6 | 0 | <0.0001% |
| Ayabudge LLC | 10 percent owner | 8191140 2.9486% | $3.61M | 1 | 10 | <0.0001% |
| Binder Gordon M | director | 160000 0.0576% | $70,480.00 | 3 | 0 | <0.0001% |
| Scheessele William John | Chief Commercial Officer | 22018 0.0079% | $9,698.93 | 3 | 0 | <0.0001% |
| Green Charles Bruce | director | 8400 0.003% | $3,700.20 | 1 | 0 | +27.83% |
| Wallace Max N. | director | 4015 0.0014% | $1,768.61 | 1 | 0 | <0.0001% |
| Dougan Brady W | director | 0 0% | $0 | 7 | 27 | <0.0001% |
| Niklason Laura E | President, CEO and Director | 0 0% | $0 | 7 | 27 | <0.0001% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$130,095 | 43 | 45.19% | $111.24M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
Humacyte, Inc. (HUMA) | $47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 83 | +60.58% | 13M | +28.06% |
| Decreased Positions | 51 | -37.23% | 3M | -6.49% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 16 | Sold Out | 630,831 | Sold Out |
| Total Postitions | 169 | +23.36% | 56M | +21.56% |
| Blackrock, Inc. | $9,654.00 | 5.13% | 9.9M | -43,653 | -0.44% | 2025-09-30 |
| Vanguard Group Inc | $7,332.00 | 3.9% | 7.52M | +520,431 | +7.43% | 2025-09-30 |
| Geode Capital Management, Llc | $3,019.00 | 1.6% | 3.1M | +147,708 | +5.01% | 2025-09-30 |
| State Street Corp | $2,348.00 | 1.25% | 2.41M | -2M | -45.16% | 2025-09-30 |
| Morgan Stanley | $2,044.00 | 1.09% | 2.1M | +720,158 | +52.31% | 2025-09-30 |
| Ubs Group Ag | $1,952.00 | 1.04% | 2M | -443,136 | -18.12% | 2025-09-30 |
| Woodline Partners Lp | $1,952.00 | 1.04% | 2M | +680 | +0.03% | 2025-09-30 |
| Two Sigma Investments, Lp | $1,332.00 | 0.71% | 1.37M | -170,797 | -11.11% | 2025-09-30 |
| Millennium Management Llc | $1,118.00 | 0.59% | 1.15M | -1M | -55.08% | 2025-09-30 |
| Susquehanna International Group, Llp | $1,114.00 | 0.59% | 1.14M | -273,500 | -19.31% | 2025-09-30 |